Erytech Pharma (NASDAQ:ERYP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.
According to Zacks, “Erytech Pharma S.A. operates as a biopharmaceutical company. It discovers and developes therapies for rare forms of cancer and orphan diseases. The company’s product pipeline consists of eryaspase, erymethionase, eryminase, ERYZYME and ERYMMUNE which are in clinical stages. It operates primarily in France and the United States. Erytech Pharma S.A. is based in France. “
A number of other analysts also recently issued reports on the stock. Cowen reiterated a “buy” rating on shares of Erytech Pharma in a report on Monday, June 25th. ValuEngine upgraded shares of Erytech Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.
A hedge fund recently bought a new stake in Erytech Pharma stock. Millennium Management LLC bought a new stake in Erytech Pharma SA (NASDAQ:ERYP) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 43,567 shares of the company’s stock, valued at approximately $959,000. Millennium Management LLC owned approximately 0.25% of Erytech Pharma at the end of the most recent quarter. Institutional investors own 25.65% of the company’s stock.
About Erytech Pharma
ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
Featured Story: Diversification For Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.